Clinical trials: Macular Edema, Diabetic
Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation
VISUPRIME® Eye Drops
The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.
- Conditions
- Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT05677685
- Testing
- VISUPRIME
- Where
- 6 sites in Italy
- Volunteers
- 78 people
- Sponsor
- VISUfarma SpA
Diabetic Retinopathy, Diabetic Eye Problems
Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
The duration of diabetes is directly related to eye complications. Diabetic retinopathy affects 80 percent of those who have had diabetes for 20 years or more.
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT04805541
- Testing
- Color Fundus Photography, Mydriatic Agent, EyeCheckup - AI Based DR Screening
- Where
- Turkey (Türkiye)
- Volunteers
- 900 people
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Diabetic Macular Edema
Gene Therapy for DME
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with Diabetic Macular Edema (DME).
- Trial name
- NCT06492876
- Testing
- FT-003
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Frontera Therapeutics
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema (DME)
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
This study is intended to assess the exposure, safety, biological activity, and durability of UBX1325, a phosphate pro-drug, and its active parent molecule (UBX0601) following a single intravitreal (IVT) injection of UBX1325 in…
- Trial name
- NCT04857996
- Testing
- UBX1325
- Where
- 22 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Unity Biotechnology, Inc.
Glaucoma, Age-Related Macular Degeneration
Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images
Eye health is of great importance for quality of life. Some eye diseases can progress and cause permanent damage up to vision loss if they are not treated early.
- Conditions
- Glaucoma, Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
- Trial name
- NCT06213896
- Testing
- Mydriatic Agent, Color Fundus Photography, EyeCheckup v2.0
- Where
- Turkey (Türkiye)
- Volunteers
- 1,528 people, healthy volunteers welcome
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Diabetic Macular Edema
The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)
This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 12 weeks.
- Trial name
- NCT05573100
- Testing
- CU06-1004
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 67 people
- Sponsor
- Curacle Co., Ltd.
Diabetic Macular Edema (DME)
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18…
- Trial name
- CONGO (NCT04697758)
- Testing
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- AsclepiX Therapeutics, Inc.
Wet Age-related Macular Degeneration, Retinal Vein Occlusion
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
- Conditions
- Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT03790852
- Testing
- KSI-301
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema
Evaluation of RC28-E Injection in Diabetic Macular Edema
This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with diabetic macular edema.
- Trial name
- NCT04782115
- Testing
- intravitreal injection of RC28-E, Conbercept
- Where
- 37 sites in China
- Volunteers
- 156 people
- Sponsor
- RemeGen Co., Ltd.
Diabetic Retinopathy, Diabetic Macular Edema
Assessment of Retinal Fundus Imaging Camera
The goal of this prospective study is to evaluate device performance when using fundus images taken from retinal fundus cameras in subjects with and without diabetic retinopathy per ETDRS level 35 and higher with or without…
- Trial name
- NCT06173232
- Testing
- Camera Imaging
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Digital Diagnostics, Inc.
Diabetic Macular Edema (DME)
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
This is a Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema
- Trial name
- NCT04739306
- Testing
- CT-P42, Eylea
- Where
- Slovakia
- Volunteers
- 348 people
- Sponsor
- Celltrion
Diabetes Mellitus, Macular Edema
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID-DME (NCT01331681)
- Testing
- VEGF Trap-Eye (BAY86-5321), Macular Laser Photocoagulation (Control)
- Where
- 73 sites in Australia, Austria and 9 more
- Volunteers
- 406 people
- Sponsor
- Bayer
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
Part A of the study is conducted to select the THR-149 dose level. Part B of the study is conducted to assess the efficacy and safety of the selected dose level compared to aflibercept, up to Month 3.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- KALAHARI (NCT04527107)
- Testing
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
- Where
- 78 sites in United States, Czechia and 6 more
- Volunteers
- 135 people
- Sponsor
- Oxurion
Refractory Diabetic Macular Edema
A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema
This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from refractory diabetic macular edema.
- Trial name
- NCT04005430
- Testing
- Episcleral Dexamethasone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Targeted Therapy Technologies, LLC
Diabetic Macular Edema
A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema
This study is designed as a Multi-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single and multiple intravitreal injections of IBI324 in subjects with DME
- Trial name
- NCT05489718
- Testing
- IBI324
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Diabetes, Diabetic Retinopathy
Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device
Diabetes affects over 37 million Americans and over 530 million people globally. Each diabetic patient needs at least one retinal exam per year starting immediately at the time of diagnosis if they have Type II diabetes (and…
- Conditions
- Diabetes, Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Eye Problems
- Trial name
- NCT05368623
- Testing
- Color fundus photograph, Optical Coherence Tomography (OCT) of the retina, Mydriatic Agent
- Where
- 3 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- RETINA-AI Health, Inc.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
This Phase IIIb, single-arm, open-label multicenter clinical in-use study in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is designed to assess the ability of the intended…
- Trial name
- NCT05569148
- Testing
- Faricimab PFS Configuration
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Diabetic Retinopathy, Diabetic Macular Edema
OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases
Evolucare OphtAI is a medical device offering automated, artificial intelligence powered, screening capabilities for Diabetic Retinopathy, Diabetic Macular Edema, Glaucoma, ARM and AMD, whose performances will by tested through…
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Age-Related Macular Degeneration, Age-related Maculopathy
- Trial name
- OPHTAI-EVAL (NCT05752045)
- Testing
- Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device
- Where
- 12 sites in France
- Volunteers
- 1,389 people
- Sponsor
- Evolucare Technologies
Diabetic Macular Edema
Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
The purpose of this study is to evaluate efficacy and safety of RC28-E compared with Aflibercept in subjects with diabetic macular edema.
- Trial name
- NCT05885503
- Testing
- RC-28E, Aflibercept
- Where
- China
- Volunteers
- 316 people
- Sponsor
- RemeGen Co., Ltd.